Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6

Pharmacogenetics

Volumn 13, Issue 3, 2003, Pages 173-181

  Yu, Ai Ming ^a   Idle, Jeffrey R ^b   Byrd, Linda G ^a   Krausz, Kristopher W ^a   Küpfer, Adrian ^b   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

5 Hydroxytryptamine; 5 Methoxytryptamine; CYP2D6; Melatonin

Indexed keywords

5 METHOXYTRYPTAMINE; CYTOCHROME P450 2D6; MELATONIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CELL REGENERATION; CELL TYPE; DEMETHYLATION; DISSOCIATION CONSTANT; DRUG RECEPTOR BINDING; ENZYME INHIBITION; EQUILIBRIUM CONSTANT; LIVER MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONIN RELEASE; SEXUAL MATURATION; STEM CELL; TRANSGENIC MOUSE;

5-METHOXYTRYPTAMINE; ANIMALS; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; HUMANS; MASS SPECTROMETRY; MICE; MICE, TRANSGENIC; MICROSOMES, LIVER; POLYMORPHISM, GENETIC; SPECTROPHOTOMETRY, ULTRAVIOLET;

MUS MUSCULUS;

EID: 0037342251     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200303000-00007     Document Type: Article

References (53)

1. Patel S, Dulluc J, Geffard M. Comparison of serotonin and 5-methoxytryptamine immunoreactivity in rat raphe nuclei. Histochemistry 1986; 85:259-263.
2. Baker GB, Martin IL, Coutts RT, Benderly A. Determination of 5-hydroxytryptamine in rat brain regions by gas-liquid chromatography with electron-capture detection. J Pharmacol Methods 1980; 3:173-179.
3. Galzin AM, Eon MT, Esnaud H, Lee CR, Pevet P, Langer SZ. Day-night rhythm of 5-methoxytryptamine biosynthesis in the pineal gland of the golden hamster (Mesocricetus auratus). J Endocrinol 1988; 118:389-397.
4. Raynaud F, Pevet P. Effect of different photoperiods on the diurnal rhythm of 5-methoxytryptamine in the pineal gland of golden hamsters (Mesocricetus auratus). J Neural Transm Gen Sect 1991; 83:235-242.
5. Rogawski MA, Roth RH, Aghajanian GK. Melatonin: deacetylation to 5-methoxytryptamine by liver but not brain aryl acylamidase. J Neurochem 1979; 32:1219-1226.
6. Beck O, Jonsson G. In vivo formation of 5-methoxytryptamine from melatonin in rat. J Neurochem 1981; 36:2013-2018.
7. Balemans MG, Bary FA, Legerstee WC, Van Benthem J. Seasonal variations in HIOMT activity during the night in the pineal gland of 21 day old male Wistar rats. J Neural Transm 1980; 49:107-116.
8. Beck O, Jonsson G, Lundman A, 5-Methoxyindoles in pineal gland of cow, pig, sheep and rat. Naunyn Schmiedebergs Arch Pharmacol 1981; 318:49-55.
9. Beck O, Borg S, Lundman A. Concentration of 5-methoxyindoles in the human pineal gland. J Neural Transm 1982; 54:111-116.
10. van Benthem J, Mans DR, Ebels I, Balemans MG. Rhythmic synthesis of various 5-methoxyindoles in the pineal gland of male adult golden hamsters, kept under the same artificial conditions throughout the year. J Neural Transm 1985; 61:219-237.
11. Raynaud F, Pevet P. Determination of 5-methoxyindoles in pineal gland and plasma samples by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1991; 564:103-113.
12. Beck O, Bosin TR. Analysis of 5-methoxytryptamine in brain by gas chromatography mass spectrometry. Biomed Mass Spectrom 1979; 6:19-22.
13. Zawilska JB, Nowak JZ. Characterization of melatonin receptors in the brain of four avian species: duck, goose, pigeon, and turkey. Gen Comp Endocrinol 1996; 101:227-234.
14. Sugden D, Pickering H, Teh MT, Garratt PJ. Melatonin receptor pharmacology: toward subtype specificity. Biol Cell 1997; 89:531-537.
15. Lang U, Aubert ML, Rivest RW, Vinas-Bradtke JC, Sizonenko PC. Inhibitory action of exogenous melatonin, 5-methoxytryptamine, and 6-hydroxymelatonin on sexual maturation of male rats: activity of 5-methoxytryptamine might be due to its conversion to melatonin. Biol Reprod 1985; 33:618-628.
16. Peroutka SJ. Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B, and 5-HT1C binding sites in rat frontal cortex. J Neurochem 1986; 47:529-540.
17. Gurevich N, Wu PH, Carlen PL. Serotonin agonist and antagonist actions in hippocampal CA1 neurons. Can J Physiol Pharmacol 1990; 68:586-595.
18. Heuring RE, Peroutka SJ. Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes. J Neurosci 1987; 7:894-903.
19. Hoyer D, Waeber C, Pazos A, Probst A, Palacios JM. Identification of a 5-HT1 recognition site in human brain membranes different from 5-HT1A, 5-HT1B and 5-HT1C sites. Neurosci Lett 1988; 85:357-362.
20. Schoeffter P, Waeber C, Palacios JM, Hoyer D. The 5-hydroxytryptamine 5-HT1D receptor subtype is negatively coupled to adenylate cyclase in calf substantia nigra. Naunyn Schmiedebergs Arch Pharmacol 1988; 337:602-608.
21. Wainscott DB, Cohen ML, Schenck KW, Audia JE, Nissen JS, Baez M, et al. Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol 1993; 43:419-426.
22. Bertrand PP, Kunze WA, Furness JB, Bornstein JC. The terminals of myenteric intrinsic primary afferent neurons of the guinea pig ileum are excited by 5-hydroxytryptamine acting at 5-hydroxytryptamine-3 receptors. Neuroscience 2000; 101:459-469.
23. Britt SG, Gonias SL, Sanders JM, Vandenberg SR. Agonist and antagonist activities of arylpiperazines at human platelet serotonin2 receptors. J Pharmacol Exp Ther 1988; 247:965-970.
24. Baxter GS, Murphy OE, Blackburn TP. Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle. Br J Pharmacol 1994; 112:323-331.
25. Craig DA, Eglen RM, Walsh LK, Perkins LA, Whiting RL, Clarke DE. 5-Methoxytryptamine and 2-methyl-5-hydroxytryptamine-induced desensitization as a discriminative tool for the 5-HT3 and putative 5-HT4 receptors in guinea pig ileum. Naunyn Schmiedebergs Arch Pharmacol 1990; 342:9-16.
26. Boess FG, Monsma FJ, Jr., Carolo C, Meyer V, Rudler A, Zwingelstein C, et al. Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacology 1997; 36:713-720.
27. Tsou AP, Kosaka A, Bach C, Zuppan P, Yee C, Tom L, et al. Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase. J Neurochem 1994; 63:456-464.
28. Li P, Pang SF, Tsang CW. Retinal 5-methoxytryptamine and 5-methoxyindole-3-acetic acid in the rat and quail: diurnal rhythms and interspecies differences. Biochem Biophys Res Commun 1997; 239:353-356.
29. Nowak JZ, Szymanska B, Zawilska JB, Bialek B. Hydroxyindole-O-methyltransferase activity in ocular and brain structures of rabbit and hen. J Pineal Res 1993; 15:35-42.
30. Masson-Pevet M, Pevet P. Cytochemical localization of type-A and -B monoamine oxidase in the rat pineal gland. Cell Tissue Res 1989; 255:299-305.
31. Young IM, Leone RM, Francis P, Stovell P, Silman RE. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. J Clin Endocrinol Metab 1985; 60:114-119.
32. Di WL, Djahanbakhch O, Kadva A, Street C, Silman R. The pineal and extra-pineal origins of 5-sulphatoxy N-acetyl-serotonin in humans. J Pineal Res 1999; 26:221-226.
33. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
34. Hadidi H, Güzey C, Idle JR. Pharmacogenetics and toxicological consequences of human drug oxidation and reduction. In: Syversen T (editor): General and Applied Toxicology. Basingstoke: Macmillan Reference; 1999, pp 215-250.
35. Gelboin HV, Krausz KW, Shou M, Gonzalez FJ, Yang TJ. A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. Pharmacogenetics 1997; 7:469-477.
36. Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 2001; 60:1260-1267.
37. Omura T, Sato R. The carbon-monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964; 239:2370-2378.
38. Forsstrom T, Tuominen J, Karkkainen J. Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS. Scand J Clin Lab Invest 2001; 61:547-556.
39. Granvil CP, Krausz KW, Gelboin HV, Idle JR, Gonzalez FJ, 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther 2002; 301:1025-1032.
40. Tyce GM. Origin and metabolism of serotonin. J Cardiovasc Pharmacol 1990; 16 (suppl 3):S1-S7.
41. Gottowik J, Cesura AM, Malherbe P, Lang G, Da Prada M. Characterisation of wild-type and mutant forms of human monoamine oxidase A and B expressed in a mammalian cell line. FEBS Lett 1993; 317:152-156.
42. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 2001; 11:237-245.
43. Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 2002; 82:1376-1387.
44. Evrard A, Malagie I, Laporte AM, Boni C, Hanoun N, Trillat AC, et al. Altered regulation of the 5-HT system in the brain of MAO-A knock-out mice. Eur J Neurosci 2002; 15:841-851.
45. Chan TY, Tang PL. Characterization of the antioxidant effects of melatonin and related indoleamines in vitro. J Pineal Res 1996; 20:187-191.
46. Poeggeler B, Thuermann S, Dose A, Schoenke M, Burkhardt S, Hardeland R. Melatonin's unique radical scavenging properties - roles of its functional substituents as revealed by a comparison with its structural analogs. J Pineal Res 2002; 33:20-30.
47. Nakagawa H, Sumiki E, Ikota N, Matsushima Y, Ozawa T. Endogenous and new synthetic antioxidants for peroxynitrite: selective inhibitory effect of 5-methoxytryptamine and lipoic acid on tyrosine nitration by peroxynitrite. Antioxid Redox Signal 1999; 1:239-244.
48. Nakagawa D, Ohshima Y, Takusagawa M, Ikota N, Takahashi Y, Shimizu S, et al. Functional modification of cytochrome c by peroxynitrite in an electron transfer reaction. Chem Pharm Bull (Tokyo) 2001; 49:1547-1554.
49. Lissoni P. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Ann N Y Acad Sci 2000; 917:560-567.
50. Lissoni P, Bucovec R, Bonfanti A, Giani L, Mandelli A, Roselli MG, et al. Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia. J Pineal Res 2001; 30:123-126.
51. Foltynie T, Sawcer S, Brayne C, Barker RA. The genetic basis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73:363-370.
52. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 1993; 87:23-28.
53. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297:400-403.